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Abstract
Introduction and Aim: Mangafodipir is a contrast agent used in magnetic resonance imaging that concentrates in the liver
and displays pleiotropic antioxidant properties. Since reactive oxygen species are involved in ischemia-reperfusion
damages, we hypothesized that the use of mangafodipir could prevent liver lesions in a mouse model of hepatic ischemia
reperfusion injury. Mangafodipir (MnDPDP) was compared to ischemic preconditioning and intermittent inflow occlusion
for the prevention of hepatic ischemia-reperfusion injury in the mouse.
Methods: Mice were subjected to 70% hepatic ischemia (continuous ischemia) for 90 min. Thirty minutes before the
ischemic period, either mangafodipir (10 mg/kg) or saline was injected intraperitoneally. Those experimental groups were
compared with one group of mice preconditioned by 10 minutes’ ischemia followed by 15 minutes’ reperfusion, and one
group with intermittent inflow occlusion. Hepatic ischemia-reperfusion injury was evaluated by measurement of serum
levels of aspartate aminotransferase (ASAT) activity, histologic analysis of the livers, and determination of hepatocyte
apoptosis (cytochrome c release, caspase 3 activity). The effect of mangafodipir on the survival rate of mice was studied in a
model of total hepatic ischemia.
Results: Mangafodipir prevented experimental hepatic ischemia-reperfusion injuries in the mouse as indicated by a
reduction in serum ASAT activity (P,0.01), in liver tissue damages, in markers of apoptosis (P,0.01), and by higher rates of
survival in treated than in untreated animals (P,0.001). The level of protection by mangafodipir was similar to that
observed following intermittent inflow occlusion and higher than after ischemic preconditioning.
Conclusions: Mangafodipir is a potential new preventive treatment for hepatic ischemia-reperfusion injury.
Citation: Coriat R, Leconte M, Kavian N, Bedda S, Nicco C, et al. (2011) Mangafodipir Protects against Hepatic Ischemia-Reperfusion Injury in Mice. PLoS ONE 6(11):
e27005. doi:10.1371/journal.pone.0027005
Editor: Holger K. Eltzschig, University of Colorado Denver, United States of America
Received May 20, 2011; Accepted October 7, 2011; Published November 2, 2011
Copyright:  2011 Coriat et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from: French Ministry for Research, Association pour la Recherche sur le Cancer (ARC), National Agency for
Valorization of Research (ANVAR), Association Transhe ´pate, Association Benoı ˆt Malassagne, and Paris-Biotech. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: frederic.batteux@cch.aphp.fr
. These authors contributed equally to this work.
Introduction
Ethics Statement
Animals received human care in compliance with institutional
guidelines under the permit number 75–1302 delivered to Dr
Carole Nicco, PhD, the 04/06/2007.
Blood loss and transfusions during liver resection have a
deleterious impact on both short and long-term outcomes [1,2].
To minimize intra-operative bleeding, surgical management of
hepatectomy requires pedicular clamping [3]. The common
drawback of clamping is hepatic ischemia-reperfusion (I/R)
injury, especially when the liver is affected by chronic hepatitis
or cirrhosis, with a risk of poor postoperative outcome [4]. Two
surgical strategies have been developed to minimize I/R
injuries: intermittent clamping (IC) and ischemic precondition-
ing (IP).
IC consists of an intermittent inflow occlusion followed by short
periods of reperfusion and has demonstrated a protective effect [5–
7]. A drawback inherent to IC is blood loss during each period of
reperfusion and the increased operative time [8]. The alternative
to IC is IP that consists of a brief period of ischemic reperfusion
applied prior to the prolonged ischemic insult. IP has demon-
strated a protective effect during liver resection in humans [9].
Studies in animal models of ischemia reperfusion have suggested
that the protective effect of IP is mediated by an enhancement in
endogeneous anti-oxidative stress mechanisms [10,11].
Liver injury following I/R has a biphasic pattern [12]. In the
initial phase, 0.5–2 h after the onset of reperfusion, reactive
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hepatocytes are activated. The late phase corresponds to self-
aggravating inflammatory injury inducing ROS [12]. Hepatocytes
injuries are most likely initiated by ROS and extracellular
chemokines [13]. ROS have been shown to exert a central role
in contributing to tissue injury after reperfusion of the ischemic
liver [14–16].
Superoxide anions (O2u
2) originating from either the mito-
chondrial respiratory chain or various cytosolic enzymes, such as
xanthine oxidase or NADPH oxidase, are generated by ischemic
hepatocytes. Superoxide anions are detoxified by superoxide
dismutase (SOD) that convert O2u
2 into H2O2 which is then
detoxified by catalase, glutathione peroxydase, or thioredoxine
[17,18]. The overproduction of ROS leads to lipid peroxidation,
damages of mitochondrial membrane [19], release of cytochrome
c into the cytoplasm followed by caspase-3 activation, and finally,
to hepatocyte apoptosis [20]. Endogenous antioxidant compounds,
such as superoxide dismutase, catalase, and glutathione can limit
the effects of ROS but quickly become overwhelmed by the large
amounts of ROS produced.
Because the oxidative stress plays such an important role in I/R
injury, we hypothesized that the administration of a molecule
endowed with antioxidative properties could be a valuable
treatment of I/R injury. SOD, catalase and GSH reductase have
been administered in animal models to counterbalance the
endogenous enzymatic depletion during hepatic ischemia-reper-
fusion [21,22]. Although the targeted delivery of SOD and
catalase to Kuppfer cells after mannosylation or succinylation
could prevent hepatic injury [18], the effectiveness of an
exogenous enzymatic supply was controversial probably because
of the insufficient delivery to the target sites. Therefore, we chose
to test mangafodipir, a non peptidic enzymatic mimic with a high
level of liver intracellular penetration. Mangafodipir (MnDPDP), a
contrast agent used in magnetic resonance imaging of the liver,
comprises a fodipir moiety, a chelate of manganese resulting from
the condensation of two pyridoxal 59 phosphate molecules [23].
The fodipir moiety binds to the pyridoxal 59 phosphate receptor
on hepatocytes and ensures a high intrahepatic concentration of
mangafodipir in the liver. In addition to the known capability of
fodipir to increase GSH levels under a variety of oxidative
conditions [24–26], we have shown that mangafodipir displays
pleiotropic antioxidant properties. Indeed, this molecule is
endowed with SOD-, catalase-, and glutathione reductase-like
activities that allow both detoxification of mitochondrial ROS and
regeneration of the GSH pool [27]. Those properties explain the
effectiveness of mangafodipir in the treatment of APAP-induced
acute liver failure in mice [28]. The aim of our study was,
therefore, to identify the therapeutic activity of mangafodipir in a
mouse model of hepatic I/R injury, versus IC and IP.
Methods
Chemicals
All chemicals were from Sigma (Saint Quentin Fallavier,
France) except for mangafodipir (MnDPDP, TeslascanH, Amer-
sham Health, Amersham, UK).
Animals
BALB/c female mice between 6 and 8 weeks of age were used
in all experimental groups (Iffa Credo, L’Arbresles, France).
Animals received human care in compliance with institutional
guidelines under the permit number 75–1302 delivered to Dr
Carole Nicco, PhD, the 04/06/2007. Hepatic ischemia was
performed as follow: animals were anesthetized with an intraper-
itoneal injection of Avertine (10 mg/kg) and laparotomy was
performed. Ischemia of the left lateral and left median lobes was
induced by a microvascular clamp for 90 minutes. Reperfusion
was initiated by removing the clamp [29].
Experimental Design
The following groups of mice were studied: Group 1: sham
(anesthesia and laparotomy) (n=9); group 2: control (90 minutes
of ischemia) (n=9); group 3: (as group 2 with intraperitoneal
administration of 10 mg/kg of mangafodipir 30 minutes prior to
ischemia) (n=9); group 4: IP(as group 2 but with preconditioning
induced by 10 minutes of ischemia followed by 15 minutes of
reperfusion [30]) (n=9); group 5: IC (six cycles of 15 minutes of
ischemia followed by 5 minutes of reperfusion [30]) (n=9).
Mice were injected intraperitoneally with 10 mg/kg of manga-
fodipir, which corresponds to the concentration used in humans as
a contrast agent [31].
Twenty four hours following ischemia, the animals were
sacrificed, blood was collected for measurement of serum
transaminase activity, and livers were removed from the peritoneal
cavities for histopathological and biochemical studies.
Mitochondrial and Cytosolic Production of O2u2
The effects of mangafodipir on intracellular ROS production
were assessed in vitro in human (HepG2) hepatocellular carcinoma
cell line. Cytosol and mitochondria from HepG2 cells (15 x10e6
cells) were seeded in 24-well plates (Costar, Corning, Inc.,
Corning, NY) and incubated for 18 hours with mangafodipir or
with culture medium alone. Levels of intracellular superoxide
anion O2u- were assessed spectrofluorometrically (Packard
Bioscience, Boston, MA, USA) by oxidation of dihydroethidium
(DHE) (Molecular Probes, Leiden, The Netherlands) as previously
described [32]. The levels of O2u- were calculated in each sample
as follows: ROS rate (arbitrary units/2*10e6 cells) = (fluorescence
intensity [arbitrary units].
Serum Aminotransferase activity
Serum activity of aspartate aminotransferase (ASAT) was used
as a marker of hepatocyte cytolysis. ASAT activity was quantified
using a standard clinical automatic analyser (Hitachi type 747,
Roche Diagnostics, Meylan, France).
Histological examination of livers
Livers were fixed overnight at 4uC in 4% paraformaldehyde in
PBS, dehydrated, paraffin-embedded, and cut at 4-mm thickness.
Hematoxylin-eosin-stained sections were used for histopathologi-
cal evaluation of hepatic injuries. Two pathologists who were not
aware of which animals received which treatment examined slides.
Lipid peroxidation assay
The concentrations of 4-hydroxyalkenals (4-HNE) and mal-
ondialdehyde (MDA) were measured in whole liver homogenates
using the lipid peroxidation kit from Calbiochem (Calbiochem,
Paris, France): whole liver homogenates were mixed with
methanol: acetonitrile and N-methyl-2-phenylindole to yield a
purple chromophore, which was measured spectrophotometrically
at 586 nm. The level of lipid peroxydation was expressed as the
amounts of 4-HNE + MDA per mg of proteins.
Measurement of hepatic GSH content
GSH levels in liver tissue were measured by the method of
Baker et al [33]. Briefly, 50 ml of whole liver extract (1 mg/mL) or
of reduced GSH (Sigma) as standard were added to 100 mLo fa
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1 mM NADPH, 5.75 mL of 100 mM NaPO4, 1 mM EDTA
buffer, pH 7.5 and 0.1 mL of GSH reductase (200 U/mL). GSH
levels were determined by measuring absorbances at 405 nm.
Cytochrome c determination
Cytochrome c concentration was determined on cytosolic
fractions or enriched mitochondrial fractions from livers of mice.
The amount of proteins in each lysate was measured using the
BSA microbiuret assay (Pierce, Bezons, France). The rat/mouse
Cytochrome c ELISA from R&D (Abingdon, Oxon, UK) was used
to determine the levels of cytochrome c in each fraction. Results
were expressed as pg of cytochrome c per mg of proteins.
Measurement of caspase-3 activity
Caspase-3 activity was measured on cytosolic fractions from
livers of mice using 400 mM of chromogenic substrate Ac-DEVD-
pNA (Calbiochem) and 200 mM of cytosolic fraction. Caspase-3
activity was calculated as the mean of the duplicate test wells
minus the value obtained for the control wells containing 200 mM
specific inhibitor.
Animal Survival
The rate of mouse survival was evaluated in groups 2 and 3 after
total hepatic ischemia (22). Segmental hepatic ischemia (70%) was
followed by the resection of the non ischemic liver lobes (30%). For
the survival time courses, animals were observed for 30 days and
sacrificed when they appeared moribund. The moribund state has
been appreciated in a blinded manner by two observers who were
not aware of which animals had received which treatment.
Statistical analysis
Results were expressed as means +/2 standard error (SEM).
The statistical significance of differences in the groups was
analysed by chi-square tests for incidence data. Paired Student’s
t-test was used for comparison of means between two groups. A
level of P,0.05 was accepted as significant. * p,0.05; ** p,0.02;
*** p,0.01; **** p,0.001 vs untreated ninety minutes’ ischemia
controls.
Results
Serum enzymatic activities
Ninety minutes’ ischemia (control) induced a 40-fold increase in
serum transaminase activityies compared to the sham-operated
group. Compared to the untreated ninety minutes’ ischemia
control group, ASAT activities were significantly lower after
administration of mangafodipir and IC (P,0.01 and p=0.01,
respectively), and not significantly different from the basal level
observed in the sham-operated group. ASAT activities in the IP
group were lower than in the control group, but the difference
between the two groups did not reach significance (Fig. 1).
Liver histological examination
After 90 minutes of continuous ischemia, large confluent areas
of tissue lysis with blood congestion in the sinusoids and leukocyte
infiltrates were observed. In the IP liver, limited and focal areas of
hepatocyte necrosis were also observed (Fig. 2), whereas the
parenchyma was almost normal after mangafodipir or IC
treatment.
Lipid Peroxidation assay
Lipid peroxidation has been used as an indirect measurement of
oxidative damage induced by ROS (24). Levels of 4-HNE and
MDA were significantly higher in the ninety minutes’ ischemia
control group than in the sham-operated group (13.361.7 mM/
mg versus 5.460.5 mM/mg, P,0.001) after liver reperfusion. In
animals treated by IC or IP, lipoperoxidation was not significantly
reduced (9.861.5 mM/mg with IC and 10.261.1 mM/mg with
IP. Only mangafodipir significantly reduced lipoperoxidation versus
the ischemia control group (7.660.3 mM/mg, P,0.01) (Fig 3).
Figure 1. Mangafodipir and intermittent clamping prevent the increase in transaminase activities following reperfusion injury.
Serum levels of aspartate amino-transferase activities (ASAT) served as markers of hepatocyte injury. ASAT levels were measured after 24 hours of
reperfusion. Bars represent means 6 SEM, nine mice in each group.
doi:10.1371/journal.pone.0027005.g001
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In the control group with continuous inflow occlusion, the
cytosolic GSH content was decreased by 55% versus the sham-
operated group. Treatment with mangafodipir, IC or IP, decreased
mitochondrial GSHcontentby only4%,14%and 30%,respectively
(P,0.001, 0.001 and 0.05, respectively versus the ninety minutes’
ischemia control group). The GSH content in the mitochondria of
liver cells was also modified following continuous inflow occlusion
and was significantly lower than in the sham-operated group
(P,0.001). Mangafodipir, IC and IP increased the mitochondrial
Figure 2. Mangafodipir and intermittent clamping prevent histological lesions of the liver following reperfusion injury. Hematoxylin-
eosin-stained sections were used for histopathological evaluation of hepatic injuries. The sections were examined at 400-fold magnification.
Representative livers from normal BALB/c mice (A), Sham-operated mice (B), ninety minutes’ ischemia control group (C), Mangafodipir (MnDPDP)-
treated group (D), IP-treated group (E) and IC-treated group (F).
doi:10.1371/journal.pone.0027005.g002
Figure 3. Prevention of lipid peroxidation following ischemia-reperfusion of the liver using on mangafodipir and intermittent
clamping. The concentrations of 4-hydroxyalkenals (4-HNE) and malondialdehyde (MDA) were measured spectrophotometrically in whole liver
homogenates. The level of lipid peroxidation was expressed as the amounts of 4-HNE + MDA per mg of proteins. Bars represent means 6 SEM; nine
mice in each group.
doi:10.1371/journal.pone.0027005.g003
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reperfusion injury. The concentrations of glutathione in cytoplasm and mitochondria of mouse liver were measured spectrophotometrically in
whole liver homogenates. The levels of reduced gluthatione were expressed as pmol per 10 mg of proteins. Bars represent means 6 SEM, nine mice in
each group. The O2u- depletion in the mitochondria (C) of HepG2 cells induced by mangafodipir (400 mM) was assessed in a kinetic experiment.
Immunofluorescence microscopy of HepG2 cells stained with oxidation of dihydroethidium (DHE) and treated for 18 h or not with mangafodipir. (D–
E) A decreased intensity of cytosol with mangafodipir in mangafodipir treated cells was observed.
doi:10.1371/journal.pone.0027005.g004
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(P,0.01, 0.001 and 0.02, respectively) (Fig 4A and 4B).
Cellular Mediators of Apoptosis
To further evaluate that mangafodipir inhibit cysolic and
mitochondrial ROS, levels of intracellular superoxide anion O2u-
in mitochondria and cytosol from HepG2 cells were assessed and
confirm a 29% and 28% ROS level decreases in mitochondria and
cytosol, respectively. (figure 4C–D)
Cellular Mediators of Apoptosis
To further evaluate the mechanisms leading to liver cell injuries,
we evaluated apoptotic liver cell death by measuring the
cytochrome c released from mitochondria into the cytosol, and
by assaying cytosolic caspase-3 activity. Ischemia/reperfusion
injuries were associated with mitochondrial collapse, as revealed
by the significant 35% decrease in the mitochondrial/cytosolic
cytochrome c ratio in the ninety minutes’ ischemia control group
versus the sham-operated group (P,0.001).The decrease in the
mitochondrial/cytosolic ratio was reduced by IP (24%), IC (16%)
and mangafodipir (9%) versus the ninety minutes’ ischemia control
group (P,0.001, 0.001 and 0.01, respectively) (Fig 5A). The
mitochondrial collapse following reperfusion injury is followed by
an increase in caspase-3 activation, as exemplified by the 9-fold
increase in caspase-3 activity in the ischemia control group versus
the sham-operated group (P,0.001). Mangafodipir, IC and IP
increased by 2.3-, 3.2- and 4.8-fold the caspase-3 activity
(P,0.001, 0.01 and 0.01, respectively) versus the ischemia control
group (Fig 5B).
Effect of mangafodipir on the Survival Rate of Mice
In the ischemia control group, 8 mice of 9 survived no longer
than 7 days and only one mouse survived longer than 30 days
(Table 1). By contrast, all animals survived more than 30 days in
the group treated by mangafodipir (P,0.001).
Discussion
The damage caused to the liver by I/R is a limiting factor in
many clinical settings such as liver surgery, transplantation, and
low-flow states. Because ROS and oxidative stress have been
shown to play a major role in organ I/R injury, the purpose of this
study was to test the hypothesis that mangafodipir, an antioxidant
molecule with pleiotropic antioxidative properties, would be
effective in preventing hepatic I/R injury.
I/R injuries were generated in a model of partial hepatic
ischemia in mice. This method produces severe hepatic I/R
injuries without mesenteric venous hypertension. Mesenteric
congestion is avoided by allowing intestinal blood flow through
right and caudate lobes, which leads to a satisfactory survival rate
with substantial I/R injuries.
Figure 5. Prevention of hepatocytes apoptosis following reperfusion injury. The mitochondrial/cytosol cytochrome c ratio (A) and caspase-
3 activities were measured in the livers of the various experimental groups and controls. Caspase-3 like activities were expressed as Units per mg of
proteins. Bars represent means 6 SEM, nine mice in each group.
doi:10.1371/journal.pone.0027005.g005
Table 1. Increasing the survival rate of mice by mangafodipir following reperfusion injury of the liver.
90 minutes of ischemia 7 days overall survival 30 days overall survival
Continuous inflow occlusion (control) 11% 0%
Mangafodipir therapy prior to ischemia 100% 100%
*Animal survival was evaluated using the model of total hepatic ischemia (37).
The rate of mouse survival was evaluated in control group (90 minutes of ischemia; n=9) and in control group with intraperitoneal administration of 10 mg/kg of
mangafodipir 30 minutes prior to ischemia (n=9) [40]. For the survival time courses, animals were sacrificed when they appeared moribund.
doi:10.1371/journal.pone.0027005.t001
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because this molecule is known to abrogate ROS-mediated
apoptosis/necrosis of hepatocytes in the murine model of
acetaminophen-induced acute liver failure [27]. Superoxide anion
has been suspected for a long time to be one of the principal actors
of liver lesions induced by I/R. Superoxide anion originates from
mitochondria or from a cytosolic enzymatic system such as
NADPH oxidase or xanthine/xanthine oxidase system. The
protective effects of SOD against experimental I/R in transgenic
mice overexpressing SOD, have established the role of superoxide
anion in I/R injuries of the liver. However, superoxide anion is
not the only ROS implicated in I/R. Indeed, high levels of
hydrogen peroxide (H2O2) are produced by Kupffer cells and by
parenchymal liver cells following I/R. H2O2 detoxification by
post-ischemic intravenous administration of GSH prevents
reperfusion injury in the rat liver after prolonged warm ischemia
[22]. Treatment with GSH prevents microcirculatory failure and
damages to hepatocytes and improves animal survival. The
protection was associated with an increased formation of plasma
GSSG, providing evidence of an accelerated detoxification of
ROS by intravenously applied GSH [22].
In our model of partial hepatic ischemia, the administration of
mangafodipir reduced serum ASAT activities and histological
lesions of the liver, diminished the leakage of mitochondrial
cytochrome c into the cytosol, and abrogated caspases-3
activation. Altogether, data indicates that mangafodipir ultimately
inhibits the apoptosis of hepatocytes that occurs during I/R.
Beneficial effects are correlated with the inhibition of ROS
production and the preservation of the GSH pool. Mangafodipir,
endowed with SOD-like and Glutathione reductase-like activities,
allows the detoxification of mitochondrial ROS, and the
regeneration of the GSH pool. Thus, the pleiotropic antioxidative
properties of mangafodipir can explain its beneficial effects in
experimental liver I/R.
The effectiveness of mangafodipir in controlling those param-
eters was higher than that of IP, which probably acts through
other undefined mechanisms. The mild burst of oxidative stress
generated during IP activates transcription factors, such as nuclear
factor-kappaB and activating protein -1 [11,34,35] that might
trigger the activity of antioxidant systems [36–38]. However,
increasing antioxidant systems through IP are very versatile and
do not allow the control of the antioxidant status of the liver as well
as by a chemical drug.
Mangafodipir has SOD-, catalase-, glutathione reductase-like
activities, which contribute to its protective effect against hepatic
I/R injury. In a recent study by Llacuna et al [39], I/R of the liver
was performed on mice treated with MnTBAP, with BSO or S-
adenosylmethionine and demonstrated that SOD mimics present
I/R lesion. Moreover, acting on the GSH metabolism by GSH, up
regulation by S-adenosylmethionine decrease I/R injuries while
GSH depletion by glutathione reductase inhibitor, BSO, poten-
tiate oxidative stress and increase I/R lesions. Since mangafodipir
is endowed with both SOD and glutathione reductase-like activity,
data indicates that the two enzymatic activities could add an effect
to prevent I/R lesions.
In addition to its pharmacological properties, mangafodipir
presents pharmacocinetic advantages. Indeed, Mangafodipir
trisodium is a tissue-specific imaging agent that concentrates in
the liver following in vivo administration. Mangafodipir trisodium is
a chelate of manganese (II) and of fodipir (DPDP), a vitamin B6
derivate. The fodipir moiety ensures high intra-hepatic concen-
tration of mangafodipir through its specific binding to vitamin B6
receptors borne by hepatocytes. As a contrast agent for liver MRI,
mangafodipir has already been safely used in human.
In conclusion, mangafodipir is a major candidate as a molecule
used for the prevention of ischemia-reperfusion injury during liver
surgery: it exerts a protective effect through its beneficial
pharmacological properties and pharmacokinetics. In addition,
compared to IC, it reduces blood loss and duration of surgery.
Furthermore, mangafodipir is readily available for clinical trials
since it has been used for decades as a contrast agent for liver MRI
in human.
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